Regnum (Regnum) Current Accrued Expense : $0.06 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Regnum Current Accrued Expense?

Regnum's Current Accrued Expense for the quarter that ended in Mar. 2023 was $0.06 Mil.

Regnum's quarterly Current Accrued Expense increased from Sep. 2022 ($0.12 Mil) to Dec. 2022 ($0.17 Mil) but then declined from Dec. 2022 ($0.17 Mil) to Mar. 2023 ($0.06 Mil).

Regnum's annual Current Accrued Expense increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.02 Mil) and increased from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.17 Mil).

Regnum Current Accrued Expense Historical Data

The historical data trend for Regnum's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Current Accrued Expense Chart

Regnum Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Current Accrued Expense

Get a 7-Day Free Trial

0.02

0.17

Regnum Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Current Accrued Expense	Get a 7-Day Free Trial															0.01	0.10	0.12	0.17	0.06

Regnum Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Regnum Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Regnum's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regnum (Regnum) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Third Avenue, 19th Floor, New York, NY, USA, 10016

Website

https://www.regnumcorp.com

Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines